MARKET

ACOR

ACOR

Acorda Thrpeutcs
NASDAQ
0.6201
-0.0187
-2.93%
Opening 13:29 12/01 EST
OPEN
0.6388
PREV CLOSE
0.6388
HIGH
0.6450
LOW
0.6101
VOLUME
64.23K
TURNOVER
25.96K
52 WEEK HIGH
2.830
52 WEEK LOW
0.2611
MARKET CAP
15.09M
P/E (TTM)
-0.0894
1D
5D
1M
3M
1Y
5Y
How Is The Market Feeling About Acorda Therapeutics?
Benzinga · 11/09 20:06
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/08 10:00
BRIEF-Acorda Therapeutics Announces Adjournment Of Special Meeting Of Stockholders
Reuters · 11/04 14:54
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
PEARL RIVER, N.Y., November 04, 2022--Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
Business Wire · 11/04 13:25
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/02 12:20
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Benzinga · 11/02 09:07
BRIEF-Acorda Therapeutics Reports Third Quarter 2022 Financial Results
Reuters · 11/01 21:17
Acorda Therapeutics Q3 EPS $(0.55) Up From $(1.43) YoY, Sales $33.51M Miss $36.97M Estimate
Benzinga · 11/01 20:37
More
About ACOR
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). INBRIJA is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. INBRIJA utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Webull offers kinds of Acorda Therapeutics Inc stock information, including NASDAQ:ACOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACOR stock methods without spending real money on the virtual paper trading platform.